Attention-Deficit Hyperactivity Disorder and Long-QT Syndrome: Risky Business.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Selective Effects of Methylphenidate on Attention and Inhibition in 22q11.2 Deletion Syndrome: Results From a Clinical Trial.The international journal of neuropsychopharmacology · 2022
   Trial
2. Psychiatric Medications and QTc Prolongation in the Pediatric Population.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2025
   Article
3. Surface Electrocardiographic Parameters of Children and Adolescents Diagnosed with Attention-Deficit/Hyperactivity Disorder in an Ambulatory Community Pediatric Center: A Focus on Cardiac Repolarization Electrocardiogram Intervals.Journal of child and adolescent psychopharmacology · 2021
   Article

Corrections and comments

• Comment on
  Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder.2015

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as